GET THE APP

..

Journal of Infectious Diseases and Medicine

ISSN: 2576-1420

Open Access

Special Issue

Pathogenesis of Emerging COVID-19
Pathogenesis of Emerging COVID-19

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, China in December 2019, and spread globally, resulting in the on-going 2019–20 coronavirus pandemic. Symptoms of COVID-19 include fever, cough, fatigue, loss of smell, difficulty in breathing, persistent chest pain, confusion, difficulty in walking, and bluish skin. The majority of cases result in mild symptoms. The virus is spread between people with close contacts, via small droplets produced by coughing, sneezing, or talking. People may infect by touching the contaminated surfaces and then touching their faces, eyes, and nose. Diagnosis can be done by real-time reverse transcription-polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Chest CT imaging also helps with diagnosis in individuals. Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), covering coughs, and keeping unwashed hands away from the face. There is no vaccine or specific antiviral treatment for COVID-19. Management of infection involves the treatment of symptoms, supportive care, isolation, and experimental measures. The World Health Organization (WHO) declared the 2019–20 coronavirus outbreak as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020.

Pathogenesis: The SARS-CoV-2 is a β-coronavirus, which is enveloped non-segmented positive-sense RNA virus (subgenus sarbecovirus, Orthocoronavirinae subfamily). Coronaviruses (CoV) are divided into four genera, including α−/β−/γ−/δ-CoV. α- and β-CoV are able to infect mammals, while γ- and δ-CoV tend to infect birds.  It was found that the genome sequence of SARS-CoV-2 is 96.2% identical to a bat CoV RaTG13, where it shares 79.5% identity to SARS-CoV. It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV to infect humans.

We are especially interested in papers that explore the issues:

  • Coronavirus
  • COVID-19
  • Pathogenesis of COVID
  • SAR-CoV-2
  • COVID Immune response
  • COVID-19 Vaccine
  • Virus
  • Public Health Emergency
  • Global Disease

Submission Process 

  • Special issue articles can include both original unpublished research articles and review articles related to the specific theme
  • Manuscripts will be accepted for publishing in the special issue only after getting approved by the peer review committee.
  • All the articles in special issues should strictly adhere to journal style and formatting.
  • Each special issue can be created with 5-7 articles.
  • All accepted manuscripts can be submitted online via https://www.scholarscentral.org/submissions/infectious-diseases-medicine.html or through an email id to  editor@hilarispublisher.com
  • Submission should be accompanied by a cover letter with reference to the concerned special issue theme.

Please visit Instruction for author’s page to know more about article formatting and guidelines: https://www.hilarispublisher.com/infectious-diseases-and-medicine/instructionsforauthors.html

Corona research fund world-wide details

https://www.fic.nih.gov/ResearchTopics/Pages/infectiousdiseases-coronavirus-cov.aspx

https://www.researchconnect.eu/coronavirus/

https://www.kff.org/coronavirus-covid-19/issue-brief/donor-funding-for-the-global-novel-coronavirus-response/

https://www.catalyze-group.com/covid-19-grants-and-funding/

https://wellcome.ac.uk/what-we-do/our-work/coronavirus-covid-19

Special Issue Editors

Alfredo Mena Lora

St. Anthony Hospital

USA

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, China in December 2019, and spread globally, resulting in the on-going 2019–20 coronavirus pandemic. Symptoms of COVID-19 include fever, cough, fatigue, loss of smell, difficulty in breathing, persistent chest pain, confusion, difficulty in walking, and bluish skin. The majority of cases result in mild symptoms. The virus is spread between people with close contacts, via small droplets produced by coughing, sneezing, or talking. People may infect by touching the contaminated surfaces and then touching their faces, eyes, and nose. Diagnosis can be done by real-time reverse transcription-polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Chest CT imaging also helps with diagnosis in individuals. Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), covering coughs, and keeping unwashed hands away from the face. There is no vaccine or specific antiviral treatment for COVID-19. Management of infection involves the treatment of symptoms, supportive care, isolation, and experimental measures. The World Health Organization (WHO) declared the 2019–20 coronavirus outbreak as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020.

Pathogenesis: The SARS-CoV-2 is a β-coronavirus, which is enveloped non-segmented positive-sense RNA virus (subgenus sarbecovirus, Orthocoronavirinae subfamily). Coronaviruses (CoV) are divided into four genera, including α−/β−/γ−/δ-CoV. α- and β-CoV are able to infect mammals, while γ- and δ-CoV tend to infect birds.  It was found that the genome sequence of SARS-CoV-2 is 96.2% identical to a bat CoV RaTG13, where it shares 79.5% identity to SARS-CoV. It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV to infect humans.

We are especially interested in papers that explore the issues:

  • Coronavirus
  • COVID-19
  • Pathogenesis of COVID
  • SAR-CoV-2
  • COVID Immune response
  • COVID-19 Vaccine
  • Virus
  • Public Health Emergency
  • Global Disease

Submission Process 

  • Special issue articles can include both original unpublished research articles and review articles related to the specific theme
  • Manuscripts will be accepted for publishing in the special issue only after getting approved by the peer review committee.
  • All the articles in special issues should strictly adhere to journal style and formatting.
  • Each special issue can be created with 5-7 articles.
  • All accepted manuscripts can be submitted online via https://www.scholarscentral.org/submissions/infectious-diseases-medicine.html or through an email id to  editor@hilarispublisher.com
  • Submission should be accompanied by a cover letter with reference to the concerned special issue theme.

Please visit Instruction for author’s page to know more about article formatting and guidelines: https://www.hilarispublisher.com/infectious-diseases-and-medicine/instructionsforauthors.html

Corona research fund world-wide details

https://www.fic.nih.gov/ResearchTopics/Pages/infectiousdiseases-coronavirus-cov.aspx

https://www.researchconnect.eu/coronavirus/

https://www.kff.org/coronavirus-covid-19/issue-brief/donor-funding-for-the-global-novel-coronavirus-response/

https://www.catalyze-group.com/covid-19-grants-and-funding/

https://wellcome.ac.uk/what-we-do/our-work/coronavirus-covid-19

Special Issue Editors

Alfredo Mena Lora

St. Anthony Hospital

USA

Google Scholar citation report
Citations: 59

Journal of Infectious Diseases and Medicine received 59 citations as per Google Scholar report

Journal of Infectious Diseases and Medicine peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward